There are 3 forms of RLT that may be used in neuroendocrine cancers
• Iodine-131 meta-iodobenzylguanidine (I-131 MIBG) primarily used f
• Yttrium90 (used less frequently for RLT, but the radionuclide may be
• Lutetium (177Lu) oxodotreotide (Lutathera®) main agent currently u
Only Lutetium (177Lu) oxodotreotide is currently licensed (2023) withi differentiated (grade 1 or grade 2), somatostatin receptor-positive gas
However MIBG is accessible for eligible patients.
Research is ongoing to develop a strong evidence base to widen the i neuroendocrine cancer primary sites, such as lung, and also other gra
There are also studies using other radioligands, for example Targeted
Further information on these and other current trials can be obtained by visiting either: • US National Library of Medicine - Clinical Trials database HERE • UK National Institute for Healthcare Research Be Part of Research database HERE
Click here to read about what Radioligand Therapy is from the Health Policy Partnership
Made with FlippingBook - Share PDF online